Knowledge Library

“Gene therapy, a promising therapeutic approach that corrects disease-causing genetic errors, has spurred an arms race among the world’s largest pharmaceutical companies. Novartis (NYSE: NVS) announced the acquisition of AxeVis for a whopping $8.7 billion in 2018. Roche (NASDAQOTH: RHHBY) agreed to acquire gene therapy developer Spark Therapeutics for $4.8 billion in early 2019. One week …Read More >

NextUp: WuXi AppTec Is Speeding Up Drug Development Worldwide The Chinese pharma company, with its deep South Philadelphia Navy Yard presence, is globally recognized for building an innovative platform that shortens drug discovery and research and development time. By Queen Muse· 7/1/2019, 8:00 a.m. “NextUp” is a weekly NextHealth PHL feature that highlights the local …Read More >

This webcast features: Sandi Schaible, Senior Director, Analytical Chemistry and Regulatory Toxicology, WuXi AppTec Leachables from single use systems have the potential to impact the quality and safety of your drug product. This presentation will help you understand those risks and how to evaluate them, the current options for test methods and what the future holds …Read More >

Leachables from single use systems can impact your drug product. This presentation will help guide you through those risks and present some options for test methods.

WuXi AppTec’s Felix Hsu on ‘Make vs Buy’ Decisions At BIO 2019, Contract Pharma had a chance to talk with WuXi AppTec’s Felix Hsu, SVP and Global Head of Advanced Therapies, about “Make vs Buy” decisions, as well as cell and gene therapy market trends.